Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00396383 · OUTCOME

Number of Participants With a Durable Graft at 12 Months Post Transplantation

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Approximately month 13

What was measured

Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation.

Analysis population: Intent to treat population includes participants who received plerixafor, underwent transplantation, and were evaluable 12 months post transplant.

Groups in this outcome

Participants With Multiple Myeloma (MM)

Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Participants With Multiple Myeloma (MM)6

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants With Multiple Myeloma (MM)6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation.
groups
  1. description
    Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.
    id
    OG000
    title
    Participants With Multiple Myeloma (MM)
param Type
NUMBER
population Description
Intent to treat population includes participants who received plerixafor, underwent transplantation, and were evaluable 12 months post transplant.
reporting Status
POSTED
time Frame
Approximately month 13
title
Number of Participants With a Durable Graft at 12 Months Post Transplantation
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice